Sysmex Corporation TSE:6869

Sysmex : HIGH DIAGNOSTIC PERFORMANCE OF THE RANDOM-ACCESS HISCL pTAU-217, Aβ42 AND Aβ40 PLASMA ASSAYS IN DETECTING AMYLOID PATHOLOGY ACROSS CLINICAL STAGES

Published

Source: MarketScreener

Presented by:

Inge M.W. Verberk1, Thomas Claessen1,2, Daniel Antwi-Berko1, Hans Heijst1, Azzam Aladdin1,
Yuko Sasaki Mori3, Roman Boeer4, Argonde C. van Harten1,2, Charlotte E. Teunissen1

  1. 1Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience
  2. 2Alzheimer Center Amsterdam, Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam,
    Amsterdam Neuroscience
  3. 3Sysmex R&D Center Europe GmbH
  4. 4Sysmex Europe SE
Academic conference:

Alzheimer's Association International Conference®: AAIC 2026

Presentation Date:

July 14, 2026

  • *Information contained in the news is current as of the date of the announcement, but may be subject to change without prior notice.
Newsroom